Luis Paz-Ares

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
October, 2024
October 2024
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  

Luis Paz-Ares
Sep 29, 2024, 06:34 | Insight
Picks from Lung Cancer Cocktail With Science by Stephen V Liu
The Lung Cancer Cocktail With Science 2024 conference took place on September 27th in Milan,…
Sep 26, 2024, 15:35 | Blog
Jarushka Naidoo: TL01 Phase III Datopotamab-Deruxtecan vs Docetaxel in second-line NSCLC
Jarushka Naidoo shared a post on X, about recent paper published in Journal of Clinical…
Sep 18, 2024, 23:22 | Insight
Stephen Liu: Update from TROPION-Lung01
Stephen Liu shared a post on X: “Update from TROPION-Lung01 presented at WCLC24 and now Journal…
Sep 14, 2024, 06:41 | Societies
Best of WCLC24
The WCLC24 took place at the San Diego Convention Center from September 7 to 10,…
Sep 12, 2024, 16:26 | Societies
35 posts not to miss from WCLC24 Day 4
The WCLC24 is took place at the San Diego Convention Center from September 7 to…
Sep 12, 2024, 09:48 | Insight
Datopotamab deruxtecan vs docetaxel for previously treated advanced NSCLC
Erman Akkus shared a post on X about a recent paper by Myung-Ju Ahn et…
Sep 10, 2024, 16:09 | Societies
Highlights from WCLC24 by Stephen V Liu Part 2
The WCLC24 is taking place at the San Diego Convention Center from September 7 to…
Sep 10, 2024, 16:04 | Societies
Insights from WCLC24 by Sarah Waliany
The WCLC24 is taking place at the San Diego Convention Center from September 7 to…
Sep 4, 2024, 06:47 | Insight
Jarushka Naidoo: Intracranial activity of Tarlatamab in 2L SCLC in Ph I DeLLphi-300 Trial
Jarushka Naidoo shared on X: "Intracranial activity of Tarlatamab in 2L SCLC in Ph I…
Aug 31, 2024, 20:07 | Insight
5 papers about lung cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Aug 9, 2024, 18:04 | Insight
Meyer May-Lucie: New publication in The Lancet reviewing the treatment of advanced lung cancer
Meyer May-Lucie, Doctor at Gustave Roussy, shared on X about a recent paper titled "New…
Jul 2, 2024, 04:16 | Insight
Olivier Calvayrac: TT-derived drug-tolerant (DT) lung cancer cells are vulnerable to FTIs
Olivier Calvayrac, Research Scientist at the Toulouse Cancer Research Center, shared a post on X…
Apr 26, 2024, 20:26 | Insight
New Paper Alert! Liposomal Irinotecan vs Topotecan for Relapsed Small Cell Lung Cancer: RESILIENT Phase 3 Trial
Liposomal Irinotecan vs Topotecan for Relapsed Small Cell Lung Cancer: RESILIENT Phase 3 Trial Authors:…
Apr 23, 2024, 23:25 | Drugs
Jarushka Naidoo: Pooled 5-year outcomes of Pembrolizumab and Chemotherapy for PDL less than 1% metastatic NSCLC in the Journal of Thoracic Oncology
Jarushka Naidoo shared on X: “Pooled 5-yr outcomes of Pembrolizumab and Chemotherapy  for PDL1<1% metastatic…
Mar 28, 2024, 19:34 | Societies
Cecilia Pompili: Personalized care in lung cancer will not be possible without multidisciplinary team and collaboration between specialities as we have seen during ELCC24
Mar 25, 2024, 15:15 | Societies
25 Posts Not To Miss From ELCC 2024
The European Lung Cancer Congress (ELCC 2024) took place in Prague, Czech Republic, from 20th…
All: 16 Posts: 1 - 100
Special Coverage